← Leaderboards
Shuiying Hu
Ohio State University
$2,114,418
Attributed
$4,868,480
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,868,480 · 2
By mechanism
R01$4,868,480 · 2
Top collaborators
- Maryam B. Lustberg5 shared
- Sharyn D Baker3 shared
- Blake Peterson3 shared
Most similar at Ohio State University
Same institution · by research overlap
- Maryam B. Lustberg$3,432,763
- William G Blum$1,308,600
- Carolyn Presley$1,438,820
- Sharyn D Baker$10,060,478
- Blake Peterson$11,402,719
Others in their field
Other Emerging Leaders on “Solid Neoplasm”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$24,099,336
- Crystal Mackall · Children'S Hosp Of Philadelphia$17,235,767
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
- John Freymann · Leidos Biomedical Research, Inc.$8,749,308
Research focus
Solid NeoplasmSide EffectPrevention StrategyPreventPropertySeveritiesIn VivoOatp TransportersPlasmaDoseDrug KineticsFutureAffectQuality Of LifeGeneticIncidenceMediatingMouse ModelPeripheral NervesPeripheral Nervous System DiseasesAntineoplastic AgentsChronicAcuteSpinal Ganglia
Grant awards (8)
Targeting neuronal transport to ameliorate vincristine neurotoxicity$652,168
R01 · FY2025 · CA · contact PI
Targeting neuronal transport to ameliorate vincristine neurotoxicity$620,870
R01 · FY2024 · CA · contact PI
Targeting neuronal transport to ameliorate vincristine neurotoxicity$645,896
R01 · FY2023 · CA · contact PI
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$569,420
R01 · FY2023 · CA · contact PI
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$569,418
R01 · FY2022 · CA · contact PI
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$584,565
R01 · FY2021 · CA · contact PI
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$602,095
R01 · FY2020 · CA
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib$624,048
R01 · FY2019 · CA